Targeting Melanoma with Cancer-Killing Viruses
Authors:
Open Access
- 31 March 2017
- journal article
- Published by Bentham Science Publishers Ltd. in The Open Virology Journal
- Vol. 11 (1) , 28-47
Abstract
Melanoma is the deadliest skin cancer with ever-increasing incidence. Despite the development in diagnostics and therapies, metastatic melanoma is still associated with significant morbidity and mortality. Oncolytic viruses (OVs) represent a class of novel therapeutic agents for cancer by possessing two closely related properties for tumor reduction: virus-induced lysis of tumor cells and induction of host anti-tumor immune responses. A variety of viruses, either in “natural” or in genetically modified forms, have exhibited a remarkable therapeutic efficacy in regressing melanoma in experimental and/or clinical studies. This review provides a comprehensive summary of the molecular and cellular mechanisms of action of these viruses, which involve manipulating and targeting the abnormalities of melanoma, and can be categorized as enhancing viral tropism, targeting the tumor microenvironment and increasing the innate and adaptive antitumor responses. Additionally, this review describes the “biomarkers” and deregulated pathways of melanoma that are responsible for melanoma initiation, progression and metastasis. Advances in understanding these abnormalities of melanoma have resulted in effective targeted and immuno-therapies, and could potentially be applied for engineering OVs with enhanced oncolytic activity in future.Keywords
This publication has 174 references indexed in Scilit:
- Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancerBritish Journal of Cancer, 2013
- A Landscape of Driver Mutations in MelanomaCell, 2012
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurrent Opinion in Immunology, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18RαGene Therapy, 2011
- A phase 2 trial of dasatinib in advanced melanomaCancer, 2010
- Hyaluronidase Expression by an Oncolytic Adenovirus Enhances Its Intratumoral Spread and Suppresses Tumor GrowthMolecular Therapy, 2010
- Impact of tumor microenvironment on oncolytic viral therapyCytokine & Growth Factor Reviews, 2010
- Intelligent Design: Combination Therapy With Oncolytic VirusesMolecular Therapy, 2010
- Expanded Anticancer Therapeutic Window of Hexon-modified Oncolytic AdenovirusMolecular Therapy, 2009